Literature DB >> 28395763

Screening for prostate cancer.

Rosalyn W Stewart1, Sergio Lizama2, Kimberly Peairs3, Heather F Sateia4, Youngjee Choi4.   

Abstract

This review comprises a general overview of the impact and risk factors for prostate cancer. Evidenced-based professional society prostate cancer screening guideline recommendations are reviewed, and our approach to a case is presented.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer screening; Prevention; Primary care; Prostate cancer; Screening guidelines

Mesh：

Substances：

Year:  2017        PMID： 28395763     DOI： 10.1053/j.seminoncol.2017.02.001

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  9 in total

Review 1.  [Familial prostate cancer and genetic predisposition].

Authors:  V H Meissner; M Jahnen; K Herkommer
Journal:  Urologe A       Date:  2021-03-15       Impact factor: 0.639

2.  Discovering Gene Signature Shared by Prostate Cancer and Neurodegenerative Diseases Based on the Bioinformatics Approach.

Authors:  Qiang Su; Bin Dai; Hanjian Zhang; Shengqiang Zhang
Journal:  Comput Math Methods Med       Date:  2022-06-28       Impact factor: 2.809

3.  Gonadorelins adherence in prostate cancer: A time-series analysis of England's national prescriptions during the COVID-19 pandemic (from Jan 2019 to Oct 2020).

Authors:  Ravina Barrett; Robert Barrett; Kalyan Dhar; Brian Birch
Journal:  BJUI Compass       Date:  2021-08-19

Review 4.  Prostate cancer screening-when to start and how to screen?

Authors:  Kimia Kohestani; Marina Chilov; Sigrid V Carlsson
Journal:  Transl Androl Urol       Date:  2018-02

Review 5.  A single-nucleotide polymorphism (rs1805087) in the methionine synthase (METH) gene increases the risk of prostate cancer.

Authors:  Xiaosong Zhang; Jilei Tang; Nan Shen; Kewei Ren
Journal:  Aging (Albany NY)       Date:  2018-10-18       Impact factor: 5.682

6.  MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.

Authors:  Cong Huang; Gang Song; He Wang; Guangjie Ji; Jie Li; Yuke Chen; Yu Fan; Dong Fang; Gengyan Xiong; Zhongcheng Xin; Liqun Zhou
Journal:  Biomed Res Int       Date:  2018-09-12       Impact factor: 3.411

7.  A Tetra-Panel of Serum Circulating miRNAs for the Diagnosis of the Four Most Prevalent Tumor Types.

Authors:  Belén Pastor-Navarro; María García-Flores; Antonio Fernández-Serra; Salvador Blanch-Tormo; Fernando Martínez de Juan; Carmen Martínez-Lapiedra; Fernanda Maia de Alcantara; Juan Carlos Peñalver; José Cervera-Deval; José Rubio-Briones; Jaime García-Rupérez; José Antonio López-Guerrero
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

8.  Potential Epigenetic Biomarkers for Prostate Cancer Screening.

Authors:  Jong-Myon Bae
Journal:  Int Neurourol J       Date:  2018-06-30       Impact factor: 2.835

9.  Update analysis on the association between Methionine synthase rs1805087 A/G variant and risk of prostate cancer.

Authors:  Wei Zhang; Ze Zhang; Hao Wu; Kai Xu; Wei Yuan; Yuan-Yuan Mi; Li Shi; Li Zuo; Yun-Feng Shi
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.